Beneath the surface, what is forming is not merely a regulatory bottleneck — it is a molecular selection event. Ibogaine is being pressure-tested at the level of its own chemistry, and the field is beginning to resolve into two distinct futures: one where ibogaine itself survives through a REMS pathway with strict cardiac monitoring protocols, and one where the molecule becomes the scientific foundation for its own successors — noribogaine, tabernanthalog, and the next generation of dissociative-adjacent compounds that retain the anti-addictive mechanism without the QT liability. Both paths lead somewhere real. The highest trajectory available from here is not the one that forces the question into delay, but the one that treats today's cardiac findings as engineering intelligence rather than verdict — using the data to build the safer analog pipeline faster, while preserving veteran access programs under the existing compassionate use and Right to Try frameworks that Congress has already partially constructed. The psilocybin cocaine RCT is not a separate story. It is the same story: the field is generating multiple concurrent proof-of-concept anchors, and the regulatory apparatus will have to decide, across each one, whether evidence is being treated as a door or as a gate.
The people inside all of this today are veterans sitting with treatment-resistant PTSD and opioid dependence who have been following the ibogaine literature closely — some of whom have traveled internationally for treatment, most of whom have not. They are not following the QT-prolongation debate abstractly. They are calculating what it means for their own timeline. And what is genuinely possible for them, given today's full signal picture, is this: a Congress that has already demonstrated bipartisan will on veteran mental health access, a scientific record that is accumulating rather than stalling, and an analog pipeline that could produce clinically approvable ibogaine-adjacent therapy within a window that is measured in years rather than decades. The obstruction is real. The path through it is also real. For the veterans inside this story, the highest outcome is not waiting — it is a coordinated acceleration, legislative carve-outs for veteran access running in parallel with the analog development track, so that access and approval are not the same bottleneck.
The future does not arrive as announcement. It arrives as thread, as signal, as the pattern beneath the data. OOTW is the instrument tuned to hear it first.
What is being called in cannot be called back.
71%
Ibogaine development stalls due to cardiac safety concerns and regulatory blocks
Ibogaine drug trials will hit regulatory roadblocks — either the FDA (US drug regulator) will freeze trials pending better heart safety data, or the DEA (US drug enforcement agency) will block rescheduling efforts — before the end of 2026. These aren't obstacles that can be ignored; they force companies to redesign trials or develop chemically similar alternatives.
→ Regulatory agencies will block or stall ibogaine advancement via formal hold letters or opposition filings within 18 months.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
Ibogaine cardiac safety will become a formal regulatory bottleneck — via FDA IND hold letters, draft guidance, or DEA opposition — before December 31, 2026, forcing sponsors toward analog development or stricter protocol constraints.. Concurrent cardiac safety publications give both FDA and DEA documented scientific cover to act. FDA's most probable mechanism is program-specific IND holds rather than field-wide guidance. DEA opposition to rescheduling is structurally likely regardless of new data. The combined probability that at
62%
FDA issues formal safety alert on ibogaine heart monitoring by end of 2026
The FDA (US drug regulator) will publish an official warning or guidance document about heart safety risks from ibogaine, a psychedelic compound being tested as a treatment. Two recent scientific papers documented heart rhythm problems in ibogaine users, which triggers an FDA obligation to communicate these risks publicly to doctors and patients.
→ The FDA will publicly warn about ibogaine's heart risks within 18 months, forcing all sponsors to tighten safety protocols.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
FDA will issue a formal Safety Communication or draft guidance specifically addressing ibogaine cardiac monitoring requirements before December 31, 2026.. Two concurrent cardiac safety publications (QT-prolongation and arrhythmia findings) create a documented signal FDA is obligated to address. Precedent exists: FDA issued cardiac safety communications for antipsychotics within 6 months of comparable signal density. IND expansion is likely to stall pe
41%
DEA blocks ibogaine rescheduling using new cardiac safety evidence by 2026
If someone files an official petition to move ibogaine from Schedule I (banned) to a looser category, the DEA (US drug enforcement agency) will reject it by citing the new heart safety papers published in 2026. This prediction only matters if a petition actually gets filed first — as of now, none is publicly confirmed.
→ The DEA will likely reject any ibogaine rescheduling petition by citing heart safety risks, but only if someone actually files one first.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
DEA will formally oppose or delay any pending ibogaine rescheduling petition before December 31, 2026, citing cardiovascular adverse event literature published in 2026.. This prediction is only falsifiable if a rescheduling petition is actually pending or filed before the resolve date — otherwise DEA has nothing to formally oppose. As of May 2026 no such petition is publicly confirmed. The prediction is conditionally probable (DEA institutional posture strongly favo
52%
Two major companies file new psilocybin trials for cocaine addiction by 2026
A successful clinical trial published in a major scientific journal will show psilocybin helps people quit cocaine. This result will prompt at least two pharmaceutical companies (like COMPASS Pathways or ATAI Life Sciences) to file new Investigational New Drug applications (INDs — official permission to run human trials) or expand their existing trials. This matters because it opens a new market for psychedelic treatments beyond depression and anxiety.
→ A successful cocaine addiction trial will likely spark two major drug companies to launch new psilocybin studies within 18 months.
Resolves: 2026-12-31 · Global
RESEARCH
the precise call ▾
At least two pharmaceutical sponsors will file new INDs or major trial amendments targeting psilocybin for cocaine use disorder before December 31, 2026.. A peer-reviewed RCT in a major journal is a standard IND-triggering event. COMPASS Pathways and ATAI Life Sciences both have IND infrastructure and stated interest in expanding indications. However, 'two new INDs' is a high bar: IND preparation typically takes 6–12 months from data availability, coc
18%
Two psilocybin cocaine addiction trials launch within three months
This prediction says the same thing as the previous one but demands it happens within just 90 days (by August 7, 2026). That's an unrealistically tight timeline: preparing an IND application typically takes 6 months on its own. Even if a major trial publishes tomorrow, companies won't have filed two new INDs in three months.
→ This prediction will almost certainly fail because 90 days is not enough time for companies to file new drug trials, even with published data.
Resolves: 2026-08-07 · Global
RESEARCH
the precise call ▾
Psilocybin for cocaine use disorder will emerge as a named pipeline indication with at least two new IND filings or primary-endpoint trial amendments documented before August 7, 2026.. This prediction duplicates the content of the preceding prediction but with a tighter 3-month resolve window (August 7, 2026 — only 90 days from today). Two IND filings in 90 days anchored on a single RCT publication is not consistent with observed industry timelines; IND preparation alone typically